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r. Temple et al. previously published their results of a randomized controlled trial that provided evidence to support improved sensory outcomes among innervated compared with noninnervated free transverse rectus abdominis musculocutaneous (TRAM) flaps after postmastectomy breast reconstruction. 1 This article presents additional data that evaluate the quality-of-life outcomes in the same patient cohort. The authors should be commended for their efforts in assessing whether variations in surgical technique, such as repair of the fourth and tenth intercostal nerves in a TRAM flap, can make a perceptible difference in patients' lives. Too often, surgeons are enamored with the technical features of an operation without carefully evaluating whether the complexity of the surgical procedure has a direct impact on patient outcomes. Our current health care economic environment mandates having patient-reported outcomes and health-related quality-of-life research to justify the added expense of increasingly complex surgical procedures.
2 Dr. Temple et al. have presented data that are much needed to critically reflect on the outcomes of breast reconstructive procedures.
The investigators have performed a thoughtful clinical trial using a randomized approach. Randomized controlled trials are the standard method for clinical research because this study design can theoretically create an equal distribution of both known and unknown confounding factors in the two treatment groups. As a result, randomized controlled trial studies are highly valued and considered level I evidence research. However, it is important for clinicians to understand the strengths and limitations of these study designs, especially as Plastic and Reconstructive Surgery introduces evidence-based medicine to the reconstructive and aesthetic community. 3 Although randomized controlled trials have inherent strengths, the validity of the data is dependent on having a sufficient number of study subjects within each treatment group. When the study sample is small, as shown in this article, it is expected that important baseline data that can confound the results will be unequally distributed in the two treatment groups. Therefore, the assumption of equal distribution of confounders is not valid, and the authors need to devote additional effort to adjust for these confounders statistically. Before planning a randomized controlled trial, the investigators should perform a power analysis a priori to establish an adequate sample size that will potentially avoid committing a type I (false-positive) or type II (false-negative) error. 4 Although a post hoc analysis can be performed, it will not solve the inadequate sample size problem after the study has been completed. Unfortunately, we have no information on whether a power analysis was performed for this study. The small sample size (eight innervated and 10 noninnervated flaps) raises much concern as to whether this study had a large enough sample size to avoid a type 1 error, in which the finding of having a difference may be caused by one or two outlier results. It can be expected that this study is markedly underpowered and the conclusions should be questioned. Therefore, simply because a study is a randomized controlled trial does not guarantee a valid study with a high level of evidence. All study designs have their inherent strengths, but without understanding the properties of the study designs proposed, researchers www.PRSJournal.commay collect data that are not valid. The randomized design cannot overcome the inherent validity problems associated with an underpowered study.
Ideally, a randomized controlled trial with a sufficient sample size would have samples of patients with even distribution of known and unknown factors that may impact the treatment outcome. Regression analysis is one statistical technique used to control for possible known confounding factors that may not be evenly distributed in the study sample. Body mass index, for example, has a well-documented impact on quality of life. 5, 6 The authors in their first article using this patient sample noted a statistically significant difference in body mass index by procedure type, with the noninnervated group having a much higher body mass index. The authors in the current article note that there was no statistically significant difference in body mass index in the two treatment groups. However, this follow-up study had only 18 of the 27 original study subjects, which is a loss of one-third of the sample. The lack of a statistically significant difference in body mass index is most likely attributable to a type II error (false-negative) resulting from an underpowered sample. The body mass index of the innervated flap group was 26.3, compared with 32.3 in the noninnervated group, which is a clinically significant difference. Body mass index should have been controlled for in the analyses because it may well account for some of the differences in quality-of-life outcomes between the two treatment groups.
The authors would have produced a much more statistically robust study if they had controlled for both patient and clinical factors that are known to influence quality-of-life outcomes. A previous study using the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument to measure quality of life in breast cancer patients found that most of the significant associations in the bivariate tests were not significant once patient and clinical factors were controlled for in the multivariate analyses. 7 For example, patient race/ethnicity has been shown to be a significant predictor of quality of life in breast cancer patients using the same Functional Assessment of Cancer TherapyBreast subscales as used in this article. 8 However, we do not know the racial/ethnic distribution of the patient sample in this study, nor was patient race/ethnicity controlled for in the analyses. Breast asymmetry has also been associated with breast cancer patients feeling stigmatized, and women with substantial postoperative asymmetry are less likely to report improved health after treatment and more likely to report lower quality of life. 9 In the current study, six of eight patients in the noninnervated TRAM flap group had complications, compared with five of 10 patients in the innervated flap group. It is unclear whether these complications resulted in different aesthetic outcomes, which could influence postoperative quality-of-life measures. The incidence of recurrent breast cancer 4 years after mastectomy is another important clinical variable not discussed that has obvious ramifications on quality-of-life outcomes. 6 Patient-reported measures of health outcomes are gaining recognition in both the local and national health policy arenas. The National Institutes of Health in 2004 formed the Patient-Reported Outcomes Measurement Information System that was aimed at establishing accurate and efficient measurement of patient-reported symptoms and other health outcomes. 10 The traditional components of the Health-Related Quality of Life questionnaire include three main dimensions of health-physical, mental, and social well-being.
11
Patient-reported questionnaires can be broad, general health questionnaires, or region-specific and disease-specific. General health questionnaires, such as the Medical Outcomes Study 36-Item Short Form Health Survey 12, 13 and EuroQol, 14 have too wide of a focus to be useful in specialized areas of plastic surgery but can be used in combination with more region-or disease-specific instruments and will provide an assessment of general health status. Ultimately, the measures should be reliable (prove the same result repeatedly in the same population under the same testing conditions), valid (measure what it is supposed to measure), responsive (able to detect significant changes over time), and feasible to apply.
Unfortunately, at the time of this study, the BREAST-Q was not available, which is the only valid quality-of-life measure specific to breast outcomes in the postmastectomy population. 15 The 36-Item Short Form Health Survey, Functional Assessment of Cancer Therapy-Breast quality-of-life instrument, and Body Image after Breast Cancer Questionnaire are very general instruments that poorly reflect the study's primary aim of measuring quality of life related to breast sensation. The differences in quality-of-life outcomes in the 36-Item Short Form Health Survey, Functional Assessment of Cancer Therapy-Breast quality-of-life instrument, and Body Image after Breast Cancer Questionnaire measures for the two treatment groups raise concern that these measures may be too general to be valid outcomes related to breast sensibility. For example, one would not expect breast sensibility to be associated with the funcVolume 124, Number 5 • Discussion tional well-being outcomes of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument B, the vulnerability and arm concerns of the Body Image after Breast Cancer Questionnaire, or the physical function and bodily pain measures of the 36-Item Short Form Health Survey. Mostly likely, factors other than breast sensibility are accounting for these differences in general quality-of-life measures.
This study serves as an introduction to evidence-based medicine. Randomized controlled trials are difficult to conduct, but researchers in plastic surgery should aim to use this methodology when appropriate. The randomized controlled trial study designs should be used for our profession's most important clinical questions because of the expense, study subject burden, ethical concerns, and researchers' effort associated with this research methodology. Therefore, before even contemplating a randomized controlled trial, the researcher should recognize potential pitfalls that can threaten the validity of the study. Key elements of successful clinical trials include an adequately powered study with sufficient sample sizes to avoid type I and type II errors, preoperative baseline measures, statistical analyses that control for potential confounding variables, and use of outcomes tools that have both face and content validity. 3 Plastic surgery is embarking on an exciting journey in evidence-based medicine. A series of tutorial special articles are forthcoming that will provide a more in-depth discussion on various components of clinical research that will improve the clinical evidence on which surgeons base treatment decisions. 
